Aarti Pharmalabs liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
4.69×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.49×1.49×2.01×1.94×1.95×
0.81×0.81×1.12×1.01×0.94×
4.28.554.394.063.1
477460665651564
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIPHARM₹823.65

Aarti Pharmalabs Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSADVENZYMESAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹7,467 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————4.69
Current Ratio1.951.942.011.491.49
Quick Ratio0.941.011.120.810.81
Cash, Equiv & ST Investments63.194.054.38.54.2
Working Capital564.2651.3665.1459.7477.3
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.